Future Drug Discovery publishes its first issue

Future Science Group (FSG) is pleased to announce the publication of the first issue of its new open access journal, Future Drug Discovery.

Future Drug Discovery is a peer-reviewed, open access journal for drug discovery and development research. Published quarterly, it provides a forum for discussion of the state of the drug discovery field, alongside research, review and methodology articles.

The journal is led by an international, expert advisory board including Jayanth Panyam (University of Minnesota, MN, USA), Steve Rees (Astrazeneca, Cambridge, UK) and Neil Jones (Cancer Research UK, London, UK), among other leading names in the field.

“Drug discovery research can be difficult to publish owing to various issues such as IP and drug failures. With the industry opening up to open access and open source, a journal that both provides both a home for research – both successes and failures – and a wider discussion of the field at large is a step in the right direction for the industry,” commented Francesca Lake, Head of Open Access Publishing at FSG.

The first issue includes:

Opinion pieces discussing the state of publishing in drug discovery, the importance of chromatographic separation in early phase discovery, the benefits of working in a science incubator and a perspective on working as an independent consultant

An interview discussing how the future of antibiotics lies in combination treatments

Commentaries detailing an open science rare diseases initiative and self-assembling technology for drug delivery

Research articles covering nanoparticles, nootropics and Rule of 5

The full first issue is available open access and can be read here: https://www.future-science.com/toc/fdd/1/1

The editorial office is now actively soliciting contributions of original research, reviews and perspective pieces for Future Drug Discovery. The journal team is also always looking to publish shorter pieces to spark the interest of our readers such as Editorials, Opinions, Commentaries, Interviews, Research Highlights, Conference Scenes and Company/Institutional/Organizational Profiles. Unsolicited article proposals are also always welcome, so if you are interested in contributing to the journal, please contact the Editor, Jennifer Straiton at [email protected]. Article processing charges are currently being waived for the journal.

Founded in 2001, FSG is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio consists of three imprints, Future Medicine, Future Science and Newlands Press, publishing both eBooks and journals. In addition to this core publishing business, FSG develops specialist knowledge networks and content hubs, enabling professionals to easily connect and collaborate with their peers in niche scientific fields.

FSG currently publishes 34 peer-reviewed journals as well as 8 knowledge networks and content hubs across a wide range of therapy area and scientific fields. Key journals include Future Microbiology, Future Oncology and the Journal of Comparative Effectiveness Research, alongside sites such as Infectious Diseases Hub, Oncology Central and The Evidence Base.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

###